

---

---

## Key Personnel

### Management Team

Mark A. Payton PhD  
*Chief Executive Officer*

Mick Hunter PhD  
*Director of Drug  
Discovery*

Mike Perkins MD  
*Director of Drug  
Development*

Roy Pettipher PhD  
*Director of Pharmacology*

Richard Armer PhD  
*Director of Chemistry*

Richard A Onyett  
*Commercial Director*

Paul Foster  
*Head of Finance &  
Administration*

### Board Members

David U'Prichard PhD  
*Chairman*

Mark A. Payton PhD  
*Chief Executive Officer*

### Non- Executive Directors

Stuart Collinson PhD

John Bell MD

Graham Boulnois PhD

Luke Evnin PhD

Ed Mascioli MD

*Oxagen Limited is a privately held biopharmaceutical company developing a pipeline of novel drugs to treat inflammatory diseases. The company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and is progressing the most promising as drug targets. The lead program, targeting a GPCR with a strong genetic association to asthma, has generated a number of promising candidate small molecules which are orally bioavailable and offer the potential to treat asthma and other respiratory and inflammatory conditions.*

## The Company

Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. The Company has approximately 20 employees and is based in Milton Park, south of Oxford.

## Technology and Product Information

Oxagen has focussed on GPCRs as a target class and has used it's heritage in human genetics to focus down the large number of GPCRs in the human genome to a subset which show a clear and

strong genetic association in man with one or more inflammatory or autoimmune conditions. To date we have identified 60 associations across five diseases, namely, asthma, autoimmune disease, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis and rheumatoid arthritis. Many GPCRs show genetic association to multiple diseases.

The GPCR targets we have prioritised by relevance to disease pathogenesis in man through clinical genetics range from orphan receptors, where the natural ligand is still unknown to well known and studied receptors against which there has been significant activity within pharma and biotech. In a number of cases the activity has been focussed on prosecution of these targets in therapeutic areas other than those in which we have demonstrated relevance and thus represent opportunities for indication switches (see partnering interests).

Oxagen's Lead Programme – CRTH2 antagonists for Asthma, allergy and inflammatory Disease.

Oxagen has identified a number of potent antagonists of the CRTH2 receptor which are highly selective small molecular weight compounds with a range of physical properties enabling multiple administration routes to treat a range of allergic and inflammatory diseases in man. To date preclinical activity has been demonstrated in a number of models of asthma and allergic and inflammatory diseases.



---

---

## Financial Information

Up until 2005 the Company had raised some £48m in private equity. In May 2005 the company closed a further series B private equity funding led by MPM Capital of \$60 million, one of the largest financings in Europe.

## Shareholders

Include MPM Capital, Bessemer Venture Partners, Red Abbey Venture Partners, The Wellcome Trust, University of Oxford, SV Life Sciences, 3i, Advent Venture Partners, Abingworth, CSFB Private Equity & Others

## Contact

91 Milton Park  
Abingdon  
Oxfordshire  
OX14 4RY  
United Kingdom

Tel: +44 (0) 1235 443300  
Fax: +44 (0) 1235 443301  
Email:  
Oxagen@oxagen.co.uk  
Web: [www.oxagen.co.uk](http://www.oxagen.co.uk)

Business Development  
Contact:  
[r.onyett@oxagen.co.uk](mailto:r.onyett@oxagen.co.uk)

The lead molecule ODC9101 is in Phase IIa clinical studies and demonstrates safety and suitability for a once a day oral product to treat, in the first instance, asthma. Other molecules in this and other series, all covered by Oxagen's patent estate are being developed for a range of other therapeutic indications including rhinitis, atopic dermatitis and allergic conjunctivitis.

## Partnering Interests

Oxagen's strategy in the near term is to develop molecules from lead optimisation through "proof of concept" phase IIa/IIb studies in man before identifying partners for further development and commercialisation and to broaden it's pipeline through collaborations and licensing. We have, therefore three major areas of partnering interest. Firstly, Oxagen intends to out-license it's lead once a day oral molecule for asthma (CRTH2 antagonist) following demonstration of efficacy in man. The molecule is currently in Phase IIa clinical studies (see above) . Secondly, We are focussed on advancing the pipeline of genetically validated GPCR targets for the development of therapies for inflammatory and autoimmune disease and are seeking drug discovery and development partnerships on these targets. These include – GPCRs for known drug targets with already marketed products where Oxagen's genetic association highlights alternative indications, GPCRs for drug targets that are current and known drug development targets and orphan GPCRs.

Opportunities exist within the Oxagen GPCR targets for indication switches of marketed drugs or drugs in earlier stages of development.

Thirdly, Oxagen welcomes approaches from partners with in-licensing opportunities on drug candidates which are complimentary to our in house expertise and existing pipeline. The primary focus for in licensing discussions is in the area of respiratory and inflammation at lead optimisation, preclinical, or Phase 1 development stages.